Medicine Recommendations

Treating excessive daytime sleepiness caused by narcolepsy (NICE TA758)

NICE TA 758 - Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy

Treating growth disturbance in children and young people aged 3 years and over (NICE TA863)

NICE TA863 - Somatrogon for treating growth disturbance in children and young people aged 3 years and over

Adult growth hormone deficiency (NICE TA64) & Growth failure in children (NICE TA188)

Sotagliflozin with insulin for treating type 1 diabetes (TA 622)

Acne Vulgaris

Nasal allergies

Adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (Dravet syndrome) in combination with clobazam and valproate (under expert supervision)

All indications

Treatment of severe osteoporosis

- in postmenopausal women;

- in adult men

at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. In postmenopausal women, strontium ranelate reduces the risk of vertebral and hip fractures.

The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks

MHRA Drug Safety Update - Strontium ranelate: cardiovascular risk—restricted indication and new monitoring requirements (March 2014)

Crohn's disease

Rheumatoid arthritis

Sero-negative spondyloarthropathy including psoriatic arthritis & psoriasis (unlicensed)

Ulcerative colitis

Cluster Headache

Psoriasis

 Psoriasis

For prophylaxis of graft rejection

Topical treatment for atopic dermatitis (NICE TA82)

NICE TA82 - Tacrolimus and pimecrolimus for atopic eczema 

MHRA Drug Safety Update - Tacrolimus ointment (Protopic): possible risk of malignancies including lymphomas and skin cancers

Erectile dysfunction

Erectile Dysfunction Post Prostatectomy